Glooko vs Harrison.ai
Side-by-side comparison of AI visibility scores, market position, and capabilities
Glooko is a digital health platform for diabetes and chronic condition management; syncs data from 250+ glucose meters, CGMs, insulin pumps, and wearables; supports remote patient monitoring for clinicians and health systems; raised $100M+;
About
Glooko is a digital health company founded in 2010 and headquartered in Palo Alto, California, that provides a comprehensive platform for diabetes and chronic condition management. The company's technology aggregates data from over 250 connected diabetes devices — including continuous glucose monitors (CGMs), blood glucose meters, insulin pumps, pens, and health wearables — into a single unified platform that serves both patients and their care teams. For patients, Glooko provides a mobile app offering personalized insights, trend analysis, and education based on their glucose, insulin, activity, and nutrition data. For healthcare providers and clinical teams, Glooko's Population Health platform enables remote patient monitoring — allowing endocrinologists, diabetes educators, and primary care physicians to track patient cohorts, identify high-risk individuals, and deliver data-driven care interventions at scale.
Harrison.ai is an Australian healthcare AI company building clinical-grade AI for radiology and pathology diagnostics; raised $129M+ AUD total at a $400M AUD valuation; its Annalise.ai radiology platform has FDA clearance and processes 5M+ studies;
About
Harrison.ai is a Sydney, Australia-based healthcare artificial intelligence company founded in 2018 by brothers Aengus and David Hallinan that builds clinical-grade AI models for diagnostic medicine, initially targeting radiology and pathology. The company''s flagship product — Annalise.ai — is a comprehensive AI platform for radiology interpretation that analyzes chest X-rays, CT scans, and other medical imaging studies to detect and flag a broad range of findings simultaneously. Unlike earlier radiology AI tools designed for single conditions, Annalise.ai is a multi-finding model trained to detect up to 124 findings in a single chest X-ray and 295 findings in chest CTs — providing a comprehensive AI second reader experience rather than a narrow single-disease detector.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.